Allogene’s Phase 2 ALPHA3 futility analysis shows cema-cel achieved higher MRD negativity versus observation in high-risk LBCL, with favorable safety and outpatient feasibility.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
Allogene Therapeutics reported interim results from the pivotal randomized Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) as first-line consolidation therapy in high-risk large B-cell lymphoma (LBCL). The planned futility analysis, triggered after the 24th patient completed the Day 45 minimal residual disease (MRD) assessment, showed higher MRD clearance with cema-cel compared with observation.
At the data cutoff, 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity versus 16.7% (2/12) in the observation arm, representing a 41.6% absolute difference. Plasma circulating tumor DNA (ctDNA) decreased by a median of 97.7% from baseline with cema-cel, compared with a 26.6% median increase in the observation arm. These findings support early intervention targeting residual disease in high-risk patients after first-line therapy.
MRD status following treatment is a strong predictor of relapse in LBCL. The ALPHA3 trial (NCT06500273) evaluates MRD-guided intervention prior to clinical relapse, identifying high-risk patients using the CLARITY MRD assay. Prior evidence shows patients achieving MRD negativity after curative-intent therapy have improved progression-free and event-free survival.
Favorable Safety and Outpatient Feasibility
Cema-cel was generally well tolerated with no serious treatment-related adverse events. No cases of cytokine release syndrome, neurotoxicity, or graft-versus-host disease were reported. Ten of twelve treated patients were managed entirely in the outpatient setting, while two brief hospitalizations were unrelated to treatment. One patient in the observation arm was hospitalized for febrile neutropenia.
Investigators noted that the absence of typical CAR T–related toxicities and the availability of an off-the-shelf product could enable broader outpatient use and earlier-line adoption.
Community Use and Baseline Risk
Community cancer centers accounted for about one-third of screening activity and cema-cel infusions, including sites with limited CAR T experience, supporting feasibility in routine practice. Baseline characteristics indicated high-risk disease in both arms, with numerically more aggressive features in the cema-cel group, including higher stage and International Prognostic Index scores.
Trial Design and Timeline
The interim analysis included the first 24 randomized patients. MRD assessments occur at Day 45, Month 3, and every three months during the first year. The primary endpoint is event-free survival, with progression-free survival and overall survival as secondary endpoints.
The study plans to enroll approximately 220 patients across more than 60 sites. Enrollment is expected to complete by the end of 2027, with an interim event-free survival analysis planned for mid-2027 and the primary analysis anticipated in mid-2028. Positive results could support a Biologics License Application submission.
Reference
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.